{'fraction_non_alphanumeric': 0.035839775122979624, 'fraction_numerical': 0.03373155305692199, 'mean_word_length': 4.718875502008032, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 54: Clinical and biochemical outcomes of gonadotropin -Releasing hormone analogue therapy in a cohort of children with central precocious puberty from Kerala

Background: Large scale studies of outcomes of Gonadotropin-releasing hormone analogue (GnRHa) therapy for Central Precocious puberty (CPP) are not available from our part of the country. Aim: To evaluate the efficacy of GnRHa with clinical and biochemical parameters in a cohort of children with CPP. Methodology: Retrospective analysis of case records of 33children (30 females and 3 males) diagnosed with CPP on GnRHa (Leuprolide acetate depot) was done. Results: CPP was idiopathic in 20 and organic in 13 children. Median age at onset of puberty was 6.75years (range 0.75 – 8.9 years) and at start of treatment was 7years. The Median duration of therapy was 2.75years (range= 5months-9years). 52% attained LH Suppression in one year and 81% in two years. 92% patients had regression in tanner's stage by a median of 11months. BA was advanced by a median of 4.45 SD which reduced to 2.8SD at the end of therapy. Duration of therapy had significant effect in halting BA progression (p=0.004). The median height centile of 86.25 at presentation normalised in 89% at treatment completion. Conclusion: GnRHa therapy in our cohort of CPP children was effective in reversing puberty and slowing bone age advancement despite a late age of onset of treatment.